Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Be3704315b08a21859c33867266cb41b0> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Be3704315b08a21859c33867266cb41b0 NCIT_P378 "NCI" @default.
- Be3704315b08a21859c33867266cb41b0 type Axiom @default.
- Be3704315b08a21859c33867266cb41b0 annotatedProperty IAO_0000115 @default.
- Be3704315b08a21859c33867266cb41b0 annotatedSource NCIT_C192171 @default.
- Be3704315b08a21859c33867266cb41b0 annotatedTarget "A bifunctional fusion protein composed of a humanized anti-programmed death ligand 1 (PD-L1) nanobody fused to a mutant form of the human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration of anti-PD-L1/TGFbetaRII fusion protein 6MW3511, the TGFbetaRII moiety targets, binds to and neutralizes TGFbeta while the anti-PD-L1 nanobody moiety simultaneously targets, binds to, and inhibits the activity of PD-L1 on the tumor cell. This prevents both TGFbeta- and PD-L1-mediated immuno-suppressive pathways signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This restores and enhances anti-tumor immune responses and inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers and play key roles in tumor immune suppression; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis. The TGFbetaRII moiety is modified to enhance the stability of the agent." @default.